129 related articles for article (PubMed ID: 32731714)
1. Optimization of pathogenetic therapy in patients with chronic obstructive lung disease.
Potyazhenko MM; Ishcheikin KY; Nastroga TV; Sokolyuk NL; Kitura OY; Gorodnytska IM
Wiad Lek; 2020; 73(4):773-776. PubMed ID: 32731714
[TBL] [Abstract][Full Text] [Related]
2. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.
Cazzola M; Rogliani P; Calzetta L; Hanania NA; Matera MG
COPD; 2017 Oct; 14(5):552-563. PubMed ID: 28753070
[TBL] [Abstract][Full Text] [Related]
3. [Effect of mucolytic therapy on the production of reactive oxygen species in the blood of patients with an exacerbation of chronic obstructive pulmonary disease].
Farkhutdinov UR; Farkhutdinov RR; Petriakov VV; Farkhutdinov ShU; Mirkhaĭdarov AM
Ter Arkh; 2010; 82(3):29-32. PubMed ID: 20564918
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of therapy efficiency in patients with combined course of copd and osteoarthritis].
Хайменова ГС; Шилкина ЛН; Бабанина МЮ; Волченко ГВ; Ткаченко МВ; Ждан ВН
Wiad Lek; 2016; 69(2 Pt 2):214-8. PubMed ID: 27487536
[TBL] [Abstract][Full Text] [Related]
5. [The effect of inhaled ambroxol treatment on clinical symptoms and chosen parameters of ventilation in patients with exacerbation of chronic obstructive pulmonary disease patients].
Jahnz-Rózyk K; Kucharczyk A; Chciałowski A; Płusa T
Pol Merkur Lekarski; 2001 Sep; 11(63):239-43. PubMed ID: 11761819
[TBL] [Abstract][Full Text] [Related]
6. [Mucolytics in acute and chronic respiratory tract disorders. II. Uses for treatment and antioxidant properties].
Kupczyk M; Kuna P
Pol Merkur Lekarski; 2002 Mar; 12(69):248-52. PubMed ID: 12053601
[TBL] [Abstract][Full Text] [Related]
7. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.
Poole P; Chong J; Cates CJ
Cochrane Database Syst Rev; 2015 Jul; (7):CD001287. PubMed ID: 26222376
[TBL] [Abstract][Full Text] [Related]
8. [A study of the mechanism of Qingre Huatan therapy in treatment of acute exacerbation of chronic obstructive pulmonary disease by improving airway inflammation and mucus hypersecretion].
Li W; Mao B; Wang G; Wang L; Chang J; Zhang Y; Wan MH; Guo J
Zhong Xi Yi Jie He Xue Bao; 2008 Aug; 6(8):799-805. PubMed ID: 18664347
[TBL] [Abstract][Full Text] [Related]
9. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial).
Malerba M; Ponticiello A; Radaeli A; Bensi G; Grassi V
Pulm Pharmacol Ther; 2004; 17(1):27-34. PubMed ID: 14643168
[TBL] [Abstract][Full Text] [Related]
10. EFFICIENT COMPREHENSIVE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATION AND POSTCOVIDAL SYNDROME IN ELDERLY PATIENTS.
Potyazhenko MM; Nastroga TV; Sokolyuk NL; Kitura OY; Motorna NM; Korpan AS
Wiad Lek; 2022; 75(6):1486-1491. PubMed ID: 35907221
[TBL] [Abstract][Full Text] [Related]
11. N-acetylcysteine and ambroxol inhibit endotoxin-induced phagocyte accumulation in rat lungs.
Nawrocka A; Papierz W; Bialasiewicz P; Stolarek R; Komos J; Nowak D
Pulm Pharmacol Ther; 1999; 12(6):369-75. PubMed ID: 10587478
[TBL] [Abstract][Full Text] [Related]
12. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.
Poole P; Black PN; Cates CJ
Cochrane Database Syst Rev; 2012 Aug; (8):CD001287. PubMed ID: 22895919
[TBL] [Abstract][Full Text] [Related]
13. [Mucolytics in acute and chronic respiratory tract disorders. I. Pathophysiology and mechanisms of action].
Kupczyk M; Kuna P
Pol Merkur Lekarski; 2002 Mar; 12(69):245-7. PubMed ID: 12053600
[TBL] [Abstract][Full Text] [Related]
14. [The combined drug ascoril in the treatment of patients with chronic obstructive pulmonary disease concurrent with coronary heart disease].
Grigor'eva NIu; Kuznetsov AN; Koroleva TV; Koroleva ME
Ter Arkh; 2013; 85(8):91-4. PubMed ID: 24137971
[TBL] [Abstract][Full Text] [Related]
15. Does ambroxol confer a protective effect on the lungs in patients undergoing cardiac surgery or having lung resection?
Wang S; Huang D; Ma Q; Chen X
Interact Cardiovasc Thorac Surg; 2014 Jun; 18(6):830-4. PubMed ID: 24623642
[TBL] [Abstract][Full Text] [Related]
16. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.
Poole P; Black PN
Cochrane Database Syst Rev; 2010 Feb; (2):CD001287. PubMed ID: 20166060
[TBL] [Abstract][Full Text] [Related]
17. Fast-track pulmonary conditioning before urgent cardiac surgery in patients with insufficiently treated chronic obstructive pulmonary disease.
Dreger H; Schaumann B; Gromann T; Hetzer R; Melzer C
J Cardiovasc Surg (Torino); 2011 Aug; 52(4):587-91. PubMed ID: 21499224
[TBL] [Abstract][Full Text] [Related]
18. [Non-drug rehabilitation of patients with chronic obstructive pulmonary disease concurrent with hypertension].
Sevostyanova EV; Nikolaev YA; Bogdankevich NV; Lusheva VG; Markova EN; Dolgova NA
Ter Arkh; 2016; 88(8):19-24. PubMed ID: 27636922
[TBL] [Abstract][Full Text] [Related]
19. Effects of ambroxol on spontaneous or stimulated generation of reactive oxygen species by bronchoalveolar lavage cells harvested from patients with or without chronic obstructive pulmonary diseases.
Teramoto S; Suzuki M; Ohga E; Ishii T; Matsui H; Matsuse T; Ouchi Y
Pharmacology; 1999 Sep; 59(3):135-41. PubMed ID: 10450068
[TBL] [Abstract][Full Text] [Related]
20. Effect of CArbocisteine in Prevention of exaceRbation of chronic obstructive pulmonary disease (CAPRI study): An observational study.
Esposito A; Valentino MR; Bruzzese D; Bocchino M; Ponticiello A; Stanziola A; Sanduzzi A
Pulm Pharmacol Ther; 2016 Apr; 37():85-8. PubMed ID: 26970503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
